Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 104

1.

Follow-up of childhood chronic myelogenous leukemia with monitoring the BCR-ABL fusion gene expression in peripheral blood.

Horváth A, Baghiu MD, Pap Z, Bănescu C, Mărginean CO, Pávai Z.

Rom J Morphol Embryol. 2011;52(3):907-13.

PMID:
21892537
[PubMed - indexed for MEDLINE]
Free Article
2.

Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.

Hardling M, Wei Y, Palmqvist L, Swolin B, Stockelberg D, Gustavsson B, Ekeland-Sjöberg K, Wadenvik H, Ricksten A.

Med Oncol. 2004;21(4):349-58.

PMID:
15579919
[PubMed - indexed for MEDLINE]
3.

[Monitoring of minimal residual disease in patients with chronic myeloleukemia: clinical value of real-time polymerase chain reaction].

Chelysheva EIu, Turkina AG, Misiurin AV, Aksenova EV, Domracheva EV, Zakharova AV, Khoroshko ND.

Ter Arkh. 2007;79(4):49-53. Russian.

PMID:
17564019
[PubMed - indexed for MEDLINE]
4.

Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.

Merx K, Müller MC, Kreil S, Lahaye T, Paschka P, Schoch C, Weisser A, Kuhn C, Berger U, Gschaidmeier H, Hehlmann R, Hochhaus A.

Leukemia. 2002 Sep;16(9):1579-83.

PMID:
12200666
[PubMed - indexed for MEDLINE]
Free Article
5.

Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience.

Braziel RM, Launder TM, Druker BJ, Olson SB, Magenis RE, Mauro MJ, Sawyers CL, Paquette RL, O'Dwyer ME.

Blood. 2002 Jul 15;100(2):435-41.

PMID:
12091333
[PubMed - indexed for MEDLINE]
Free Article
6.

Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL.

Ross DM, Branford S, Moore S, Hughes TP.

Leukemia. 2006 Apr;20(4):664-70.

PMID:
16482210
[PubMed - indexed for MEDLINE]
7.

Dose modification of imatinib by monitoring the level of BCR-ABL transcript in chronic myelogenous leukemia.

Ishikawa I, Kato C, Harigae H, Sugawara T, Tomiya Y, Yamada M, Ishizawa K, Kameoka J, Miyamura K, Sasaki T.

Tohoku J Exp Med. 2006 Dec;210(4):355-63.

PMID:
17146202
[PubMed - indexed for MEDLINE]
Free Article
8.

Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia.

Wang L, Pearson K, Pillitteri L, Ferguson JE, Clark RE.

Br J Haematol. 2002 Sep;118(3):771-7.

PMID:
12181044
[PubMed - indexed for MEDLINE]
9.

Molecular monitoring of response to imatinib (Glivec) in chronic myeloid leukemia patients: experience at a tertiary care hospital in Saudi Arabia.

Khalil SH, Abu-Amero KK, Al Mohareb F, Chaudhri NA.

Genet Test Mol Biomarkers. 2010 Feb;14(1):67-74. doi: 10.1089/gtmb.2009.0126. Erratum in: Genet Test Mol Biomarkers. 2010 Apr;14(2):283.

PMID:
19943786
[PubMed - indexed for MEDLINE]
10.

Which method better evaluates the molecular response in newly diagnosed chronic phase chronic myeloid leukemia patients with imatinib treatment, BCR-ABL(IS) or log reduction from the baseline level?

Qin YZ, Jiang Q, Jiang H, Li JL, Li LD, Zhu HH, Lai YY, Lu XJ, Liu YR, Jiang B, Huang XJ.

Leuk Res. 2013 Sep;37(9):1035-40. doi: 10.1016/j.leukres.2013.06.003. Epub 2013 Jun 26.

PMID:
23810191
[PubMed - indexed for MEDLINE]
11.

Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.

Paschka P, Müller MC, Merx K, Kreil S, Schoch C, Lahaye T, Weisser A, Petzold A, König H, Berger U, Gschaidmeier H, Hehlmann R, Hochhaus A.

Leukemia. 2003 Sep;17(9):1687-94.

PMID:
12970765
[PubMed - indexed for MEDLINE]
12.

Comparison of FISH and quantitative RT-PCR for the diagnosis and follow-up of BCR-ABL-positive leukemias.

Bao F, Munker R, Lowery C, Martin S, Shi R, Veillon DM, Cotelingam JD, Nordberg ML.

Mol Diagn Ther. 2007;11(4):239-45.

PMID:
17705578
[PubMed - indexed for MEDLINE]
13.

Hematological and molecular response evaluation of CML patients on imatinib.

Gupta A, Prasad K.

J Assoc Physicians India. 2007 Feb;55:109-13.

PMID:
17571739
[PubMed - indexed for MEDLINE]
14.

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.

Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, Cortes J, O'Brien S, Nicaise C, Bleickardt E, Blackwood-Chirchir MA, Iyer V, Chen TT, Huang F, Decillis AP, Sawyers CL.

N Engl J Med. 2006 Jun 15;354(24):2531-41.

PMID:
16775234
[PubMed - indexed for MEDLINE]
Free Article
15.

Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.

Cortes J, Talpaz M, O'Brien S, Jones D, Luthra R, Shan J, Giles F, Faderl S, Verstovsek S, Garcia-Manero G, Rios MB, Kantarjian H.

Clin Cancer Res. 2005 May 1;11(9):3425-32.

PMID:
15867244
[PubMed - indexed for MEDLINE]
Free Article
16.

Simple and reliably sensitive diagnosis and monitoring of Philadelphia chromosome-positive cells in chronic myeloid leukemia by interphase fluorescence in situ hybridization of peripheral blood cells.

Yanagi M, Shinjo K, Takeshita A, Tobita T, Yano K, Kobayashi M, Terasaki H, Naoe T, Ohnishi K, Ohno R.

Leukemia. 1999 Apr;13(4):542-52.

PMID:
10214860
[PubMed - indexed for MEDLINE]
17.

Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group.

Hochhaus A, Reiter A, Saussele S, Reichert A, Emig M, Kaeda J, Schultheis B, Berger U, Shepherd PC, Allan NC, Hehlmann R, Goldman JM, Cross NC.

Blood. 2000 Jan 1;95(1):62-6.

PMID:
10607685
[PubMed - indexed for MEDLINE]
Free Article
18.

Comparative analysis of interphase FISH and RT-PCR to detect bcr-abl translocation in chronic myelogenous leukemia and related disorders.

Tbakhi A, Pettay J, Sreenan JJ, Abdel-Razeq H, Kalaycio M, Hoeltge G, Miller ML, Tubbs RR.

Am J Clin Pathol. 1998 Jan;109(1):16-23.

PMID:
9426513
[PubMed - indexed for MEDLINE]
19.

Quantitative BCR-ABL1 RQ-PCR fusion transcript monitoring in chronic myelogenous leukemia.

Moore FR, Rempfer CB, Press RD.

Methods Mol Biol. 2013;999:1-23. doi: 10.1007/978-1-62703-357-2_1.

PMID:
23666687
[PubMed - indexed for MEDLINE]
20.

[Monitoring bcr/abl mRNA levels in imatinib mesylate treated chronic myeloid leukemia patients by real-time quantitative RT-PCR].

Qin YZ, Ruan GR, Liu YR, Li JL, Fu JY, Wang H, Chang Y, Jiang B, Jiang Q, Jiang H, Qiu JY, Chen SS, Lu DP.

Zhonghua Xue Ye Xue Za Zhi. 2005 Jan;26(1):1-5. Chinese.

PMID:
15946498
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk